

Clinical Trials in China are Faster Than US

By Therapy Area and Phase – Single Country Trials


7 MonthsAvg. Time Saved
China vs US (Phase I)**53%**Avg. Faster in China
Across across Therapy
Areas (TAs)**2–3x**Phase I Speed Advantage
China vs US (non-
oncology)**34%**Largest Gap: Oncology
17.23 vs 26.16 months

AVERAGE DURATION BY THERAPY AREA

Phase I – Average Duration of Clinical Trials

Duration in months – single-country trials


● United States ● China



Phase II – Average Duration of Clinical Trials


Duration in months – single-country trials

● United States ● China



CHINA SPEED ADVANTAGE BY THERAPY AREA

Phase I



Phase II



KEY FINDINGS

Phase II trials maintain China's advantage (**14–30 months vs 18–38 months in the US**), though the gap **narrows to 3–7 months** as trial complexity increases.

Protocol requirements standardise across both markets at this phase, reducing the administrative efficiency advantage China holds in earlier phases.

Acronyms

CNS – Central Nervous System
Infectious – Infectious disease
NBA – New Biological Entity

NMA – New Molecular Entity
Metabolic – Metabolic Disorder

GAP COMPRESSION

PHASE I
AVG. GAP**~7mo**52% faster in
ChinaPHASE II
AVG. GAP**~5mo**21% faster in
China